Skip to main content

Table 1 Mechanisms of ferroptosis in urological cancers

From: Roles of ferroptosis in urologic malignancies

Cancer type Biomolecular mechanism References
Prostate cancer HDECR1 silencing induced ferroptosis by accumulation of PUFAs and then promoting ROS generation [38]
Silencing of PANX2 promoted ferroptosis by suppressing the expression of Nrf2 [41]
PI3K/AKT/mTOR inhibited ferroptosis via upregulating SREBP1/SCD1 [50]
HSPB1inhibited ferroptosis by promoting iron uptake and increasing lipid ROS production [65]
Bicalutamide-iron combination induced ferroptosis [28]
The combination of erastin and docetaxel induced ferroptosis [111]
CHAC1 inhibits cell viability and increases the sensitivity of prostate cancer cells to docetaxel by inducing ferroptosis [67]
Therapy-induced lipid uptake and remodeling underpin GPX4 dependence and ferroptosis hypersensitivity [70]
Kidney cancer VHL/HIF-2α induced ferroptosis via elevating lipid peroxidation levels through HILPDA [73]
TAZ silencing reduce sensitivity to erastin-induced ferroptosis by downregulating the expression of EMP1-NOX4 [79]
ACOT8 inhibited ferroptosis [86]
Repression of SUV39H1 induced ferroptosis via enhancing DPP4 activity [89]
The low-expression of NCOA4 conferred ccRCC cells resistance to ferroptosis by increasing FTH and FTMT expression levels [96]
GPX1 induced ferroptosis in KIPP [101]
ART induced ferroptosis and enhanced the anti-tumor effect of sunitinib [118, 119]
Bladder cancer CPNPs targeted to EDNRB via EDN3-CPNPs and thereby induced ferroptosis [121]
Quinazolinyl-arylurea derivatives induced ferroptosis through ROS generation and GSH depletion [122]